drugset / Trial / NCT04540770
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001
RandomizedSequentialTriple-blindTreatment
Summary
This is a first-in-human, two-part, Phase 1 study that will characterize the safety, tolerability, PK, and immunogenicity of HuL001.
Timeline
- Start
- 2021-08-31
- Primary completion
- 2022-03-04
- Completion
- 2024-01-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HuL001 | Monoclonal antibody | 1 mg/kg | — |
| Subject | HuL001 | Monoclonal antibody | 3 mg/kg | — |
| Subject | HuL001 | Monoclonal antibody | 5 mg/kg | — |